Tratamiento adyuvante con corticosteroides versus antibióticos para la endoftalmitis aguda después de un procedimiento intraocular
Resumen
Antecedentes
La endoftalmitis se refiere a la infección grave dentro del ojo que incluye el humor acuoso o el humor vítreo, o ambos, y que pone en riesgo la visión. La mayoría de los casos de endoftalmitis son exógenos (es decir, se deben a la inoculación de microorganismos de una fuente exterior), y la mayoría de las endoftalmitis exógenas son agudas y ocurren después de una intervención intraocular. La base del tratamiento es la administración emergente de antibióticos intravítreos de amplio espectro. Debido a sus efectos antiinflamatorios, se ha propuesto que la administración conjunta de corticosteroides con antibióticos es beneficiosa en el tratamiento de la endoftalmitis.
Objetivos
Evaluar los efectos de los antibióticos combinados con corticosteroides versus los antibióticos solos para el tratamiento de la endoftalmitis aguda después de la cirugía intraocular o la inyección intravítrea.
Métodos de búsqueda
Se realizaron búsquedas en el Registro Cochrane central de ensayos controlados (Cochrane Central Register of Controlled Trials; CENTRAL) (que contiene el Registro de ensayos del Grupo Cochrane de Salud ocular y de la visión [Cochrane Eyes and Vision]) (2021, número 8); MEDLINE Ovid (de 1946 a agosto de 2021); Embase Ovid (1980 a agosto de 2021); LILACS (Latin American and Caribbean Health Sciences Literature database) (1982 a agosto de 2021); el registro ISRCTN (explorado en agosto de 2021); ClinicalTrials.gov (explorado en agosto de 2021); y la Plataforma de registros internacionales de ensayos clínicos de la OMS (explorada en agosto de 2021). No se aplicaron restricciones de fecha ni de idioma en las búsquedas electrónicas de ensayos.
Criterios de selección
Se incluyeron los ensayos controlados aleatorizados (ECA) que compararan la efectividad de los corticosteroides adyuvantes con los antibióticos solos en el tratamiento de la endoftalmitis aguda diagnosticada clínicamente después de la cirugía intraocular o la inyección intravítrea. Se excluyeron los ensayos de participantes con endoftalmitis endógena, a menos que los desenlaces se comunicaran según la fuente de la infección. No se establecieron limitaciones en cuanto al método ni el orden de la administración, la dosis, la frecuencia ni la duración de los antibióticos ni de los corticosteroides.
Obtención y análisis de los datos
Se utilizó la metodología estándar de Cochrane y la certeza del conjunto de evidencia para seis desenlaces se evaluó mediante el método GRADE.
Resultados principales
En esta actualización de la revisión se incluyeron cuatro ECA (con un total de 264 ojos de 264 participantes). Los estudios se realizaron en Sudáfrica, India y los Países Bajos. Todos los estudios administraron dexametasona intravítrea para el tratamiento adyuvante con corticosteroides y una combinación de dos antibióticos intravítreos que proporcionaron cobertura grampositiva y gramnegativa para la antibioticoterapia. Se consideró que dos ensayos tuvieron en general bajo riesgo de sesgo y los otros dos estudios tuvieron en general riesgo de sesgo incierto debido a la falta de información con respecto a los métodos de estudio. Sólo un estudio se registró en un registro de ensayos clínicos.
Aunque ninguno de los estudios incluidos informó sobre el desenlace principal de resolución completa de la endoftalmitis como se definió en el protocolo de la revisión, un estudio informó sobre el éxito combinado anatómico y funcional (es decir, proporción de participantes con presión intraocular de al menos 5 mmHg y agudeza visual de al menos 6/120). La evidencia de certeza muy baja no indicó diferencias en el éxito combinado al comparar los corticosteroides adyuvantes con los antibióticos solos (razón de riesgos [RR] 1,08; intervalo de confianza [IC] del 95%: 0,80 a 1,45; 32 participantes). La evidencia de certeza baja de dos estudios indicó que la dexametasona adyuvante podría dar lugar a un buen resultado visual (agudeza visual de Snellen 6/6 a 6/18) a los tres meses en comparación con los antibióticos solos (RR 1,95; IC del 95%: 1,05 a 3,60; 60 participantes); sin embargo, la evidencia fue menos concluyente a los 12 meses (RR 1,12; IC del 95%: 0,92 a 1,37; dos estudios; 195 participantes; evidencia de certeza baja). Los investigadores de un estudio informaron mejorías en la agudeza visual, pero no fue posible calcular el efecto del tratamiento adyuvante con corticosteroides porque no proporcionaron ninguna estimación de la precisión. Solo un estudio examinó la presión intraocular (PIO). La evidencia indica que la dexametasona adyuvante podría reducir ligeramente la PIO después de 12 meses de intervenciones (diferencia de medias ‐1,90; IC del 95%: ‐3,78 a 0,07; un estudio; 167 participantes; evidencia de certeza baja). Tres estudios informaron sobre los eventos adversos (desprendimiento de retina, hipotonía, vitreorretinopatía proliferativa, seclusión pupilar, moscas flotantes y pliegues). La cantidad total de eventos adversos fue 14 de 111 (12,6%) en los que recibieron dexametasona versus 12 de 116 (10,3%) en los que no la recibieron. Solo fue posible realizar un análisis agrupado para la aparición de desprendimiento de retina: cualquier diferencia entre los dos grupos de tratamiento fue incierta (RR 1,41; IC del 95%: 0,53 a 3,74; 227 participantes; evidencia de certeza baja). Ningún estudio informó sobre desenlaces relacionados con los costes.
Conclusiones de los autores
La evidencia actual disponible sobre la efectividad del tratamiento adyuvante con corticosteroides versus antibióticos solos para la endoftalmitis aguda después de la cirugía intraocular no es suficiente. No se encontraron estudios que hubieran reclutado casos de endoftalmitis aguda después de inyección intravítrea. Un análisis combinado de dos estudios indica que el uso de corticosteroides adyuvantes podrían suponer una probabilidad mayor de tener un buen desenlace visual a los tres meses, en comparación con no administrar corticosteroides adyuvantes. Sin embargo, si se tiene en cuenta que la mayoría de los intervalos de confianza cruzaron la línea de ningún efecto y que esta revisión estuvo limitada en el alcance y la aplicabilidad para la práctica clínica, no es posible concluir en este momento si la administración de los corticosteroides adyuvantes es efectiva. Los ensayos futuros deben examinar si los corticosteroides adyuvantes podrían ser útiles en ciertos contextos clínicos, por ejemplo, según el tipo de microorganismo causal o la etiología. Estos estudios deben incluir desenlaces que consideren los síntomas del paciente y la exploración clínica, informar los desenlaces de una manera uniforme y consistente y tener un seguimiento a corto y a largo plazo.
PICO
Resumen en términos sencillos
Corticosteroides más antibióticos frente a antibióticos solos para el tratamiento de la endoftalmitis aguda después de la cirugía ocular o las inyecciones en el ojo
¿Cuál es el objetivo de esta revisión?
El objetivo de esta revisión Cochrane fue determinar si el uso de corticosteroides además de antibióticos es más eficaz que utilizar antibióticos solos para la endoftalmitis aguda (infección dentro del globo ocular que puede provocar la pérdida de la visión) después de la cirugía ocular o las inyecciones en el ojo. Se buscaron todos los estudios que respondían a esta pregunta y se encontraron cuatro estudios.
Mensajes clave
No está claro si el uso de corticoides además de antibióticos es útil o perjudicial en comparación con el uso de antibióticos solos para tratar la endoftalmitis aguda después de la cirugía ocular o las inyecciones en el ojo.
¿Qué se estudió en la revisión?
La endoftalmitis es poco frecuente, pero es importante que las personas que se someten a cirugía o a inyecciones en el ojo conozcan los riesgos y que sus médicos sepan cómo tratarlos mejor, ya que puede dar lugar a pérdida de la visión. Esta afección es causada con mayor frecuencia por la entrada de bacterias al ojo durante, o unos pocos días después de la cirugía o la inyección. Tan pronto como se sospecha la endoftalmitis, por lo general se obtiene una muestra del líquido de dentro del ojo (y del líquido drenado en los casos graves) y se inyectan en el ojo antibióticos que cubren la mayoría de los tipos de bacterias. Aunque el uso de antibióticos está ampliamente aceptado, el uso de corticoides adicionales para tratar la endoftalmitis es motivo de debate. Los corticoides podrían ayudar a reducir la inflamación dentro del ojo en las personas con endoftalmitis. Se analizó si la administración de corticoides además de los antibióticos afecta los desenlaces de los pacientes.
¿Cuáles son los resultados principales de la revisión?
Se encontraron cuatro estudios de Sudáfrica, India y los Países Bajos. Casi todos los participantes de los estudios tuvieron endoftalmitis después de la cirugía de cataratas. Los cuatro estudios compararon dexametasona inyectable (un corticosteroide) más dos antibióticos en el ojo con inyectar solo antibiótico en el ojo. evidencia de certeza baja mostró que más participantes del grupo que recibió dexametasona tuvieron un buen desenlace visual a los tres meses después del tratamiento que en el grupo de solo antibióticos, pero la evidencia fue poco clara a los 12 meses. Los efectos del uso de corticoides sobre la resolución de la endoftalmitis y los efectos perjudiciales no estuvieron claros. Debido a la baja fiabilidad de la evidencia en la mayoría de los desenlaces, no está claro si los médicos deben utilizar corticoides con antibióticos para tratar la endoftalmitis después de una operación en el ojo.
¿Cuál es el grado de actualización de esta revisión?
Se buscaron estudios publicados hasta el 17 de agosto de 2021.
Authors' conclusions
Summary of findings
| Combined steroid and antibiotic therapy compared with antibiotics alone for acute endophthalmitis after intraocular procedure | ||||||
| Population: eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection) Settings: ophthalmology clinic or hospital Intervention: steroids plus antibiotics Comparison: antibiotics alone | ||||||
| Outcomes* | Illustrative comparative risks** (95% CI) | Relative effect | No. of participants | Certainty of the evidence | Comments | |
|---|---|---|---|---|---|---|
| Assumed risk | Corresponding risk | |||||
| Antibiotics alone | Combined steroid and antibiotic therapy | |||||
| Complete resolution of endophthalmitis at 3 months' follow‐up | 813 per 1000 | 878 per 1000 | RR 1.08 | 32 | ⊕⊝⊝⊝ | Assessed as combined anatomical and functional success, where anatomical success was defined as IOP of at least 5 mmHg, and functional success was defined as visual acuity of at least 6/120 |
| Visual acuity 6/6 to 6/18 at 3 months' follow‐up | 300 per 1000 | 585 per 1000 | RR 1.95 | 60 | ⊕⊕⊝⊝ |
|
| Visual acuity 6/6 to 6/18, or LogMAR 0.3 or better at 12 months' follow‐up | 627 per 1000 | 710 per 1000 (704 to 750) | RR 1.12 | 195 | ⊕⊕⊝⊝ |
|
| Improvement in visual acuity at 3 months' follow‐up | See comment | Investigators of 1 study reported improvement in visual acuity, but the effect of adjunctive steroid therapy could not be estimated because the study investigators did not provide standard deviations or standard errors. | ||||
| Intraocular pressure at 12 months' follow‐up | The mean IOP was 15.8 mmHg. | The mean IOP was on average 1.90 lower (95% CI −3.78 to 0.07). | － | 167 | ⊕⊝⊝⊝ |
|
| Adverse events at 3 to 12 months' follow‐up | 52 per 1000 | 72 per 1000 | RR 1.41 | 227 | ⊕⊕⊝⊝ | Data are for retinal detachment. Other reported adverse events included hypotony (2/29 participants), proliferative vitreoretinopathy (1/29 participants), seclusion of pupil (1/29 participants), floaters (3/167 participants), and pucker (5/167 participants). |
| Costs associated with the interventions at 3 months' follow‐up | No data were available for this outcome. |
| ||||
| *The primary follow‐up time point for the review was 1 month; however, none of the included trials reported outcomes at this time point. Data are presented for the follow‐up time point for which data were available. CI: confidence interval; IOP: intraocular pressure; RR: risk ratio | ||||||
| GRADE Working Group grades of evidence | ||||||
| 1Downgraded (−1) for unclear risk of bias in the trials. | ||||||
Background
Description of the condition
Endophthalmitis is a rare but potentially visually devastating condition that is defined as infection in the intraocular cavities (i.e. aqueous or vitreous humor, or both) (Durand 2013). A variety of pathogens, including bacteria, viruses, fungi, or parasites, can cause the infection; the culprit pathogens differ somewhat by the mechanism of infection (Keynan 2012). Most cases of endophthalmitis are exogenous; possible routes of infection include surgery, intravitreous injection, trauma, corneal infection, and glaucoma‐filtering bleb infection (Sadaka 2012). Postoperative endophthalmitis is the most common type of exogenous endophthalmitis (Keynan 2012). While endophthalmitis is a possible complication of any intraocular surgery, 90% of postoperative endophthalmitis is due to cataract surgery, as it is the most frequent intraocular surgery (Lemley 2007). Endogenous endophthalmitis, which makes up 2% to 15% of endophthalmitis cases, occurs when organisms spread hematogenously from a distant infection site to the eye (Keynan 2012). The most common primary sites of infection are the liver, lung, and endocardium (Jackson 2014).
Epidemiology
The reported incidence of postoperative endophthalmitis varies widely, but available data indicate that the rate of endophthalmitis has been very low in recent years. Analyses of Medicare claims data in the USA showed that while the annual rate of post‐cataract surgery endophthalmitis increased from 1.79 (95% confidence interval (CI) 1.46 to 2.18) to 2.62 (95% CI 2.22 to 3.07) cases per thousand surgeries between 1994 and 2000 (West 2005), it decreased from 1.32 (95% CI 1.27 to 1.38) to 1.11 (95% CI 1.06 to 1.16) per thousand surgeries between 2003 and 2004 (Keay 2012), and was stable between 2006 and 2011 (Du 2014). More recently, the Intelligent Research in Sight Registry found that the rate of endophthalmitis after cataract surgery was 0.08% (0.8 per 1000 surgeries) for 2013 and 2014 combined (Coleman 2015). Also, there were no cases of endophthalmitis following 21,501 office‐based cataract surgeries performed at Kaiser Permanente Colorado from 2011 to 2014 (Ianchulev 2016). Reported incidences for other types of exogenous endophthalmitis are between 0.006% and 0.16% for intravitreous injection, between 0.3% and 0.7% for trabeculectomy, 2.0% for glaucoma drainage surgery, and between 0.9% and 17% for traumatic injury to the globe (Sadaka 2012; Stein 2008).
Risk factors for exogenous endophthalmitis include host factors and factors associated with the procedure. Some preoperative risk factors are male gender, older age, black and Native American race, immunocompromized states (e.g. diabetes, chronic steroid use), and recent history of periocular infections (e.g. blepharitis, conjunctivitis) (Hatch 2009; Keay 2012; Keynan 2012). The main intraoperative risk factor is increased intraocular exposure to the patient’s adnexal and ocular surface flora, which increases with surgical complexity and complications such as posterior capsule rupture and vitreous loss (Hatch 2009; Mamalis 2002). Possible reasons for the decline in the early 2000s therefore include improved surgical techniques, sterility, and prophylactic antibiotics (Barry 2013). A multicenter study across nine European countries showed that the use of antibiotic prophylaxis with intracameral cefuroxime at the end of cataract surgery decreased the rate of endophthalmitis from 0.35% to 0.05% (ESCRS Study 2007). Higher rates of endophthalmitis are also associated with surgeries performed by surgeons with lower annual volume and fewer years of experience (Keay 2012).
Clinical presentation and diagnosis
Postoperative endophthalmitis usually presents within one to two weeks after surgery (acute type), but can also present a few weeks or months after surgery (chronic type) (Keynan 2012). On average, endophthalmitis presents five days after intravitreous injection (Lyall 2012; Simunovic 2012). While endogenous endophthalmitis occasionally affects both eyes, exogenous endophthalmitis affects only the eye that was exposed to the insult (Jackson 2003; Keynan 2012). The most common symptoms, regardless of the mechanism, are eye pain, red eye, and decreased vision. People with exogenous endophthalmitis usually feel well otherwise and are afebrile (Durand 2013). On physical examination, endophthalmitis presents with eyelid and conjunctival swelling, injected conjunctiva, corneal edema, and poor view of the fundus due to inflammation in the aqueous or vitreous humor, or both (Durand 2013; Keynan 2012). Hypopyon, the accumulation of white blood cells in the anterior chamber, is found in over 80% of cases (Lalwani 2008).
The main concern following endophthalmitis is persistent vision loss despite treatment. Visual outcome is highly dependent on the causative organism, with any streptococci causing the worst outcomes, and coagulase‐negative staphylococci causing milder cases (Durand 2013). Overall, approximately half of eyes affected by postcataract endophthalmitis do not regain a visual acuity of 20/40 or better, and 10% will lose useful vision (5/200 or worse) (EVS Group 1995). As streptococci cause a higher rate of postinjection endophthalmitis than postcataract endophthalmitis, postinjection endophthalmitis is associated with poorer visual outcomes (Simunovic 2012).
The diagnosis of endophthalmitis is made clinically, but is confirmed by a positive aqueous or vitreous culture. A vitreous specimen is preferable because it has a higher detection rate than an aqueous specimen (54.9% versus 22.5%) (Barza 1997). Nevertheless, a negative culture, which occurs in about 30% of cases, does not exclude the diagnosis (Durand 2013).
Specimen collection is performed by either needle aspirate (an office procedure) or by vitrectomy (performed in the operating room) (Durand 2013). Vitrectomy is considered a useful diagnostic as well as therapeutic method, as it is the fastest way of removing an infection from the vitreous humor. It is favored in patients with severe vision loss (i.e. worse than hand motion) and rapidly worsening vision, or those whose endophthalmitis is likely to be caused by more virulent strains (Barza 1997; Durand 2013).
Description of the intervention
Following specimen collection, endophthalmitis is immediately treated with antibiotics. Intravitreous administration of antibiotics is recommended, as other routes (e.g. topical, subconjunctival, intravenous) have been shown to be less effective (Durand 2013; Packer 2011). While the antibiotic regimen ideally targets the antibiotic sensitivities of the causative organism, it may not be possible to distinguish between different organisms from the presenting symptoms and signs alone. Broad‐spectrum antibiotics (i.e. vancomycin plus ceftazidime or amikacin) are therefore typically used first. If there is no improvement in 48 hours, the culture results dictate whether to give the patient another injection of vancomycin or ceftazidime (Durand 2013).
The use of steroids as adjunctive therapy for endophthalmitis remains controversial. The most commonly used and widely studied steroid is dexamethasone (Bui 2014).
How the intervention might work
Gram‐positive bacteria cause the vast majority of cases of postoperative and postinjection endophthalmitis. Most of these cases are caused by coagulase‐negative staphylococci, which are commonly found in the normal flora of the ocular surface (Callegan 2002; Keynan 2012). All gram‐positive pathogens, except vancomycin‐resistant Enterococcus, are susceptible to vancomycin. Most gram‐negative pathogens that are responsible for bacterial endophthalmitis can be treated with an oxyimino‐cephalosporin (e.g. ceftazidime) or an aminoglycoside (e.g. amikacin) (Han 1996; Kunimoto 1999). These antibiotics are bacteriocidal (i.e. they destroy bacteria directly), in contrast to bacteriostatic antibiotics, which work by inhibiting bacterial growth and replication.
It has been hypothesized that steroids may be beneficial in the treatment of endophthalmitis due to their anti‐inflammatory effect. Experimental studies suggest that intraocular inflammation is incited by the growth of organisms and the antibiotic‐induced release of bacterial cell walls and cell wall components. While an inflammatory response is crucial to the clearance of the infecting organism, this response may result in irreversible damage of the sensitive photoreceptor cells and other secondary damage (Callegan 2002; Callegan 2006). Steroids decrease inflammation by inhibiting migration of macrophages, disruption of vascular membranes, and production of inflammatory mediators (Sadaka 2012). In a rat model of endophthalmitis, a higher level of expression of inflammatory mediators tumor necrosis factor alpha (TNF‐α), interleukin 1 beta (IL‐1β), and interferon gamma (IFN‐γ) was associated with worse clinical presentation (Petropoulos 2006). Targeting both the infection and subsequent inflammatory response could have synergistic effects and lead to more rapid resolution of endophthalmitis and improvement in vision.
One argument against using steroids as adjunctive therapy is that they may worsen infection control, especially with fungal infections, due to the immunosuppressive properties of steroids. However, a retrospective review of 20 people with postcataract or post‐traumatic fungal endophthalmitis showed no difference in the visual outcomes of those who received intravitreous dexamethasone versus those who did not (Majji 1999). Furthermore, there was no statistically significant difference in mean vitreous vancomycin concentration among people with presumed postoperative bacterial endophthalmitis who were treated with versus without intravitreous dexamethasone (Gan 2005).
Why it is important to do this review
Although endophthalmitis is a rare complication of intraocular surgery and intravitreous injection, its treatment is an important clinical issue due to the large number of people who undergo these procedures and the poor visual outcomes after endophthalmitis. Antibiotics are well established as the mainstay of treatment, but the role of steroids remains unclear. Most literature on the use of steroids as adjunctive therapy are reports of preclinical or retrospective case studies; randomized controlled studies on this topic tend to have small sample sizes. By consolidating results across multiple studies in this review, we aimed to determine whether combination therapy with antibiotics and steroids has an obvious benefit over monotherapy with antibiotics. We also planned to address the question of whether there are certain clinical settings in which adjunctive therapy with steroids may be particularly useful in treating endophthalmitis.
Objectives
To assess the effects of antibiotics combined with steroids versus antibiotics alone for the treatment of acute endophthalmitis following intraocular surgery or intravitreous injection.
Methods
Criteria for considering studies for this review
Types of studies
We conducted this review according to our published Cochrane protocol (Kim 2016). We included randomized controlled trials (RCTs) in our primary analyses.
Types of participants
We included trials with participants who had clinically diagnosed endophthalmitis within three months of undergoing any intraocular surgery or intravitreous injection (acute endophthalmitis). There was no restriction regarding the result of the vitreous or aqueous culture. We excluded trials with participants with endogenous endophthalmitis, unless outcomes were reported separately by source of infection.
Types of interventions
We included trials that compared antibiotics and steroids versus antibiotics alone for the management of acute postprocedure endophthalmitis. There was no restriction on the method of administration, dose, frequency, or duration of antibiotics or steroids. In participants who received both antibiotics and steroids, the two treatments could have been administered simultaneously, or one type of treatment could have been administered before the other treatment.
Types of outcome measures
Primary outcomes
The primary outcome of the review was complete resolution of endophthalmitis one month after the initiation of therapy. We considered complete resolution as resolution of associated symptoms or hypopyon, or both, but we also accepted definitions used by the investigators of the included trials. We based our primary analysis on one‐month outcomes to evaluate whether using steroids as adjunctive therapy provides any benefit in the short term. We also compared outcomes at three, six, and 12 months whenever data were available.
Secondary outcomes
-
Proportion with best‐corrected visual acuity (BCVA) 20/40 (LogMAR 0.30) or better one month after the initiation of therapy.
-
Improvement in BCVA, defined as a proportion with a gain of 2 lines or more from baseline on a LogMAR chart or equivalent, at one month.
-
Mean change in intraocular pressure (IOP) from baseline at one month. When the mean one‐month change in IOP was not reported, we used the mean IOP at one month, as long as the baseline IOP was similar between intervention groups.
-
Proportion with IOP less than 21 mmHg at one month.
Adverse events
We evaluated ocular and systemic adverse effects relating to antibiotic or steroid use that were reported in the included trials.
Economic data
We did not conduct formal cost‐effectiveness analyses, but we compared the costs associated with the interventions when data were available.
Search methods for identification of studies
Electronic searches
The Cochrane Eyes and Vision Information Specialist conducted systematic searches in the following databases. There were no study design, language, or publication year restrictions. The date of the search was 17 August 2021.
-
Cochrane Central Register of Controlled Trials (CENTRAL; 2021, Issue 8) (which contains the Cochrane Eyes and Vision Trials Register) in the Cochrane Library (searched August 2021) (Appendix 1)
-
MEDLINE Ovid (1946 to August 2021) (Appendix 2)
-
Embase Ovid (1980 to August 2021) (Appendix 3)
-
LILACS (Latin American and Caribbean Health Science Information database (1982 to August 2021) (Appendix 4)
-
ISRCTN registry (www.isrctn.com/editAdvancedSearch; searched August 2021) (Appendix 5)
-
US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (www.clinicaltrials.gov; searched August 2021) (Appendix 6)
-
World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (www.who.int/ictrp; searched August 2021) (Appendix 7)
Searching other resources
We searched the reference lists of included trials to identify additional relevant trials. We did not search conference proceedings for the specific purposes of this review because they are searched annually by Cochrane Eyes and Vision, and all reports from trials identified are included in CENTRAL.
Data collection and analysis
Selection of studies
Two review authors (SE, KK) independently assessed the titles and abstracts of all records identified by the literature searches. We categorized each record as 'definitely relevant,' 'possibly relevant,' or 'definitely not relevant.' For records assessed as 'definitely relevant' or 'possibly relevant,' we obtained the full‐text report and grouped them into studies. Two review authors independently reviewed each study and classified each study as 'include,' 'exclude,' or 'unsure.' Any discrepancies between review authors were resolved by discussion at each stage of selection. We documented studies that were excluded following review of the full‐text reports, along with their reasons for exclusion, in the Characteristics of excluded studies table. For studies assessed as ‘unsure’ after review of the full‐text reports, we contacted the study authors for clarification. In cases where we received no response after two weeks, we classified the study based on available information.
Data extraction and management
We extracted and recorded data‐related study methods, participant characteristics, and outcomes from the selected trials onto standard paper data collection forms. We pilot‐tested the forms on one study before using them for all of the included studies.
Two review authors (SE, KK) independently extracted the data, resolving any discrepancies by discussion. One review author entered the data into RevMan Web (RevMan Web 2022), and a second review author checked the data entry.
Assessment of risk of bias in included studies
Two review authors (SE, KK) independently assessed the risk of bias of each included study according to Chapter 8 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2017). We considered the following risk of bias domains.
-
Selection bias: random sequence generation, allocation concealment before randomization
-
Performance bias: masking of study participants and personnel
-
Detection bias: masking of outcome assessors
-
Attrition bias: loss to follow‐up
-
Reporting bias: selective outcome reporting
-
Other potential sources of bias (e.g. funding source, sponsor's involvement in trial)
We evaluated each domain for each trial as low, high, or unclear risk. Any discrepancies between review authors were resolved by discussion.
Measures of treatment effect
We measured treatment effects based on the types of data as described in Chapter 9 of the Cochrane Handbook for Systematic Reviews of Interventions (Deeks 2017), which included the following.
Dichotomous data
We reported the proportions of participants with complete resolution of endophthalmitis, improvement of BCVA, IOP less than 21 mmHg, and adverse effects. We calculated risk ratios (RRs) with 95% CIs to estimate treatment effects.
Continuous data
Outcomes with continuous data included mean IOP and mean change in IOP. We calculated mean differences with 95% CIs to estimate treatment effects.
Qualitative data
We described types of adverse effects and economic data qualitatively whenever quantitative description was not possible.
Unit of analysis issues
The individual (one study eye per participant) was the unit of analysis. There were no unit of analysis issues because each person was randomized to a treatment, and only one eye was affected.
Dealing with missing data
We contacted study investigators to request unpublished data, clarify unclearly reported data, and/or provide reasons for missing data or loss to follow‐up. When we did not receive a response within two weeks, we used the information available in the published reports. We did not impute data for the purposes of this review. When we were unable to assume data were missing at random, we documented the outcomes with missing data and commented on potential implications in the Discussion section of the review. We referred to Chapter 16 of the Cochrane Handbook for Systematic Reviews of Interventions for guidelines on how to interpret missing data (Higgins 2017).
Assessment of heterogeneity
We assessed clinical and methodological heterogeneity by examining variations in study characteristics (e.g. methodology, participant characteristics, interventions compared, follow‐up duration). We used the I2 statistic to assess the degree of statistical heterogeneity across studies. When the I2 statistic was greater than 50%, we considered the impact of heterogeneity to be substantial. We also performed a visual assessment of the forest plot to assess heterogeneity, with poor overlap of study estimates and CIs indicating heterogeneity.
Assessment of reporting biases
Had we included 10 or more studies in a meta‐analysis, we would have created funnel plots in RevMan Web to assess publication bias. We evaluated selective outcome reporting as part of the risk of bias assessment. We planned to compare outcomes reported in the included studies with outcomes reported in the study protocols, published design and methods papers, or clinical trial registry records, when these were available.
Data synthesis
We presented the results in a narrative summary when there was substantial clinical or methodological heterogeneity, or when statistical heterogeneity and assessment of the forest plots indicated that meta‐analysis was not appropriate. In the absence of substantial heterogeneity, we combined the results of included studies and estimated treatment effects using meta‐analysis with a random‐effects model, or with a fixed‐effect model when the outcome was available from fewer than three studies.
Subgroup analysis and investigation of heterogeneity
We planned to perform subgroup analysis and investigate heterogeneity by type of intraocular procedure (e.g. cataract, glaucoma, retina), mode of steroid delivery, mode of antibiotic delivery, class of antibiotic used, and use of pars plana vitrectomy, when sufficient data were available.
Sensitivity analysis
We planned to conduct sensitivity analyses to evaluate the impact of excluding studies at high risk of bias in one or more domains, studies with only unpublished outcome data, and industry‐funded studies, when sufficient data were available.
Summary of findings and assessment of the certainty of the evidence
A summary of findings table provides key findings regarding the certainty of evidence, the magnitude of effect of the interventions examined, and the sum of available data on all primary and secondary outcomes. Two review authors (SE, KK) independently assessed the certainty of evidence for each outcome using the GRADE approach (GRADEpro GDT). Any discrepancies were resolved by discussion.
Results
Description of studies
Results of the search
We presented the detailed results of the original search in the previously published version of this review (Kim 2017). Briefly, we included three studies (six reports); identified one ongoing study (two reports); and excluded four studies (four reports) from 1540 records identified by our search of the databases in December 2016.
We performed an updated electronic database search on 17 August 2021, which yielded 337 unique records. After title and abstract screening, we retrieved nine full‐text reports for further review. We included one study (one report) and excluded eight studies (eight reports). The one newly included study was previously listed as an ongoing study (Manning 2018). Overall, we included four studies (nine reports) and excluded 12 studies (12 reports). A study flow diagram is shown in Figure 1.
Study flow diagram.
Included studies
This review includes four RCTs (Albrecht 2011; Das 1999; Gan 2005; Manning 2018). In all trials, one eye per participant was randomized. Two trials stratified participants based on etiology groups: the groups for Albrecht 2011 were "post cataract," "bleb‐related," and "other" (trauma related, endogenous, post‐pars plana vitrectomy), while the groups for Das 1999 were "postoperative" and "post‐traumatic." No studies were industry funded.
Types of participants
We included a total of 264 participants in this review update after the exclusion of 13 participants from the "bleb‐related" group and 17 participants from the "other" group in Albrecht 2011, as well as 34 participants from the "post‐traumatic" group in Das 1999. We excluded the "bleb‐related" group because bleb‐related endophthalmitis usually occurs months to years after glaucoma surgery. All of the included studies enrolled participants with a similar clinical diagnosis of suspected bacterial endophthalmitis. Except for one participant in the "postoperative group" who had a penetrating keratoplasty prior to being diagnosed with endophthalmitis, all participants in Das 1999 had postcataract endophthalmitis. The inclusion criteria for both Gan 2005 and Manning 2018 stated that the cataract surgery must have been performed within six weeks of the onset of endophthalmitis and with the expectation that postoperative visual acuity would be 20/100 or better, Gan 2005, or better than 20/100 (Manning 2018). Albrecht 2011 and Das 1999 did not report a maximum time period between the date of surgery and onset of endophthalmitis. However, Albrecht 2011 reported the mean delay of presentation as 20.25 days when including three chronic cases, and 8.6 days when excluding chronic cases. It was not possible to exclude the participants with chronic cases from this review. All of the included studies excluded any person with suspected fungal endophthalmitis. The studies were conducted in the following countries: South Africa (Albrecht 2011), India (Das 1999), and the Netherlands (Gan 2005; Manning 2018). Albrecht 2011 and Das 1999 enrolled participants who were similar in age (mean age of about 60), while Manning 2018 and Gan 2005 enrolled an older patient population (mean age of about 75 and 80, respectively). Both males and females were included in all studies. Baseline characteristics were similar between intervention groups in Albrecht 2011 and Manning 2018. The other two studies did not report statistics comparing baseline characteristics between intervention groups. The overall positive culture rates were 53%, 68%, and 69% for Albrecht 2011, Manning 2018, and Gan 2005, respectively. The positive culture rate for the postoperative group in Das 1999 was 56%.
Types of interventions
All trials used intravitreous dexamethasone with intravitreous antibiotics in the steroid group. The choice of antibiotics differed by study: vancomycin and ceftazidime in Albrecht 2011, vancomycin and amikacin in Das 1999, and vancomycin and gentamicin in Manning 2018 and Gan 2005. In each trial, the control group received the same intravitreous antibiotics as the steroid group. Participants in the control group for Manning 2018, Albrecht 2011, and Gan 2005 received antibiotics in a placebo solution, while participants in the control group in Das 1999 received intravitreous antibiotics without a placebo solution. No participants in Albrecht 2011 had a vitrectomy, while all participants in Das 1999 had vitrectomies. All participants with a baseline visual acuity at light perception only, and some participants with complications in Gan 2005 and Manning 2018 had vitrectomies. The trials also differed as to whether another injection of intravitreous dexamethasone and antibiotics was provided. Participants in Albrecht 2011 received a second injection of dexamethasone and antibiotics after 48 to 72 hours as required. Some participants in Das 1999 received another injection of intravitreous antibiotics, but no participants received additional intravitreous dexamethasone. In Gan 2005 and Manning 2018, the injection of antibiotics and dexamethasone or placebo was repeated once in all participants three to four days later. Other additional interventions are detailed in the Characteristics of included studies tables.
Types of outcomes
Primary outcome
No studies reported on our primary outcome, complete resolution of endophthalmitis. However, Das 1999 reported a somewhat similar outcome they termed "combined anatomical and functional success." This outcome was defined as the total percentage of participants with an IOP of at least 5 mmHg (i.e. anatomical success) and a BCVA of at least 6/120 (i.e. functional success). The time point for this outcome was unclear, but Das 1999 reported that visual acuity was measured at baseline as well as one, four, and 12 weeks after surgery. Other outcomes reported by Das 1999 involved quantitative inflammation scoring based on the clinical appearance of the cornea, anterior chamber, iris, and the vitreous. However, these outcomes were reported for postoperative and post‐traumatic participants as a whole (while combined anatomical and functional success were reported for each group separately), and were not included in the evidence for this review.
Secondary outcomes
Although no study investigators reported the proportion of participants with BCVA of 20/40 (LogMAR 0.30) or better one month after the initiation of therapy as proposed in this review, Manning 2018 reported the percentage of participants in each visual outcome category and mean IOP at one year. Albrecht 2011 reported the percentage of participants in each of the following Snellen visual acuity groups at three months: group 1 (6/6 to 6/18), group 2 (6/24 to 6/60), group 3 (worse than 6/60). Gan 2005 reported the number of participants in each of the following Snellen visual acuity groups at three and 12 months: light perception (LP) to hand motion (HM), counting fingers (CF), 0.1 to 0.25, 0.4 to 1.0. We combined the three‐month Snellen visual acuity data by converting the percentage of participants into number of participants for each visual acuity group for Albrecht 2011 and regrouping the visual acuities for Gan 2005 using the cut‐offs reported in Albrecht 2011. The "post cataract" group from Albrecht 2011 and all participants from Gan 2005 were included in the meta‐analysis. We also categorized 12‐month visual acuities from Gan 2005 into the groups used for the three‐month visual acuities (i.e. 6/6 to 6/18, 6/24 to 6/60, worse than 6/60). For both the three‐ and 12‐month visual acuity outcomes, we compared only the proportion of participants in group 1 (6/6 to 6/18) with those not in group 1 because this comparison was the most clinically useful. Although Manning 2018 reported BCVA, neither Albrecht 2011 nor Gan 2005 specified whether the visual acuities that they reported were 'best‐corrected.'
While no studies reported improvement in BCVA as a proportion with a gain of 2 lines or more, Albrecht 2011 reported mean number of lines of improvement on a Snellen visual acuity chart for the "post‐cataract" group. For each participant, the number of lines of improvement was determined by comparing the visual acuity at three months with the visual acuity at admission. While the Snellen visual acuities at baseline, three months, and 12 months were provided for all participants in Gan 2005, it was not possible to calculate the number of lines of improvement. Some participants had a baseline visual acuity of light perception, which does not have an equivalent visual acuity on the Snellen chart.
Except for what was included in the "combined anatomical and functional success" outcome, no outcomes related to visual acuity or IOP were reported by Das 1999. The remaining three studies did not report outcomes related to IOP.
Adverse events
Three studies reported adverse events in participants (Albrecht 2011; Gan 2005; Manning 2018). Das 1999 did not report any adverse events.
Economic data
No studies reported costs associated with the interventions.
Excluded studies
We excluded 13 studies after full‐text review; reasons for their exclusion are provided in the Characteristics of excluded studies table. In summary, we excluded seven studies because they were not RCTs and five studies because they investigated the use of adjunctive corticosteroids for the purpose of prophylaxis. The remaining study was excluded because it examined early versus delayed intravitreal corticosteroids for the treatment of acute postoperative endophthalmitis (Koehrer 2016).
Risk of bias in included studies
A risk of bias summary assessment is shown in Figure 2.
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Allocation
We assessed three trials as at low risk of bias for reporting of random sequence generation procedures (Albrecht 2011; Das 1999; Manning 2018), and two trials at low risk of bias for allocation concealment before randomization (Albrecht 2011; Manning 2018). In two studies, allocation was performed by the pharmacy based on computer‐generated random sequences (Albrecht 2011; Manning 2018). In Das 1999, randomly generated assignments were placed in sealed envelopes and opened by circulating nurses just before the preparation of the intraocular solutions. However, the risk of allocation concealment was unclear because the article does not mention whether the envelopes were sequentially numbered or opaque or whether they were opened sequentially. No information on random sequence generation or allocation concealment, or both, was provided in Gan 2005, so we assessed the risk of selection bias as unclear.
Masking (performance bias and detection bias)
We assessed Albrecht 2011 as at low risk of performance bias because a label hid the injection assignment from the participants and the surgeon. After receiving clarification from the trial author over email that visual acuities were measured by nursing staff without any knowledge of the trial, we also assessed Albrecht 2011 as at low risk of detection bias. We judged Manning 2018 as having low risk of performance and detection bias because the study authors claimed that participants, study personnel, and outcome assessors were masked with the use of similar vials containing indistinguishable clear fluids. We classified the risk of performance and detection bias as unclear for the other two trials because the masking of participants and personnel administering the injection, as well as outcome assessors, was not clearly described.
Incomplete outcome data
Das 1999 reported no losses to follow‐up or adverse events, therefore we assessed the risk of attrition bias as low. We also assessed Gan 2005 as having a low risk of attrition bias because only one participant was lost to follow‐up at 12 months, and the numbers of adverse events were similar between the steroid and placebo groups. In Manning 2018, all participants who were randomized were included in the intention‐to‐treat analysis, except for the erroneous inclusion of one participant each group; we judged this study as having low risk of attrition bias. We assessed the risk of attrition bias as unclear for Albrecht 2011 because four out of 62 participants in the placebo group were lost to follow‐up, and the reasons for loss to follow‐up were not reported (and were unknown to the trial author when asked by email). A modified intention‐to‐treat analysis was performed in which participants were analyzed by assigned treatment groups, but those without outcome information at three months' follow‐up were removed.
Selective reporting
A clinical trial registry record was available for one study, but it was unclear if the prespecified outcomes were fully reported in the final paper (Manning 2018). We judged this study as at unclear risk of bias. We assessed the three remaining trials as at unclear risk of reporting bias because no trial protocols or clinical trial registry records were available to compare the planned outcomes with the reported outcomes. Furthermore, Das 1999 reported visual acuity outcomes differently than described in the methods section of the study report. Instead of reporting visual acuity measurements at one, four, and 12 weeks postoperatively, Das 1999 reported a combined rate of functional success (visual acuity of at least 6/120) and anatomical success (IOP of at least 5 mmHg). It was not possible to verify whether the rate of functional and anatomical success was a planned outcome because we did not have access to the original study protocol.
Other potential sources of bias
One study stopped enrolling participants prematurely because the manufacturer of dexamethasone withdrew it from the markets (Gan 2005). We assessed the risk of bias as unclear for this study. We identified no other potential risk of bias in the remaining studies (Albrecht 2011; Das 1999; Manning 2018); none of these studies reported industry funding or other funding sources that could have introduced a conflict of interest.
Effects of interventions
Of a total of 264 randomized participants, 259 participants were analyzed, of which 127 participants received intravitreous steroids in addition to intravitreous antibiotics and 132 participants received only intravitreous antibiotics.
Resolution of endophthalmitis
In one study, 26 (32.1%) participants in the dexamethasone group and 27 (31.4%) participants in the placebo group showed no bacterial growth in vitreous biopsy at one year (risk ratio (RR) 1.02, 95% confidence interval (CI) 0.66 to 1.60; 167 participants; Analysis 1.1) (Manning 2018). However, it was not explicitly reported if those participants were culture‐positive or ‐negative at baseline, resulting in no analysis performed for this outcome. While no other included study reported on complete resolution of endophthalmitis, Das 1999 reported on the rate of combined anatomical and functional success. Anatomical success was defined as IOP of at least 5 mmHg, and functional success as visual acuity of at least 6/120. Among participants with postoperative endophthalmitis, 87.5% (14 out of 16) of those who received intravitreous dexamethasone and intravitreous antibiotics achieved anatomical and functional success, compared with 81.5% (13 out of 16) of the intravitreous antibiotics‐alone group (RR 1.08, 95% CI 0.80 to 1.45; Analysis 1.1). For an unknown reason, the percentage of participants who achieved combined success in the dexamethasone group was slightly higher (i.e. 93.8%; 15 out of 16) if calculated from Das 1999's Table 3 compared to the percentage reported in the results text of the study. We chose to include the percentage from the results text in the review. We graded the certainty of the evidence as very low (−1 for risk of bias, −1 for indirectness, −1 for imprecision).
Visual acuity
Three studies assessed visual acuity outcomes in people with endophthalmitis after cataract surgery (Albrecht 2011; Gan 2005; Manning 2018). In two studies (Albrecht 2011; Gan 2005), participants who received intravitreous dexamethasone and antibiotics were more likely to have a good visual outcome (6/6 to 6/18) compared with those in the antibiotics‐alone group at three months (RR 1.95, 95% CI 1.05 to 3.60; 2 studies; N = 60; Analysis 1.2; Figure 3). Two studies reported visual acuity at 12 months following treatment (Gan 2005; Manning 2018). The estimated risk ratio of having a good visual outcome (6/6 to 6/18, or LogMAR 0.3 or better) at 12 months was 1.12 (95% CI 0.92 to 1.37; 2 studies; N = 195; Analysis 1.2; Figure 3). Although I2 may represent substantial heterogeneity (I2 = 67%) in this analysis, we have presented the pooled estimate because only two studies are included (i.e. low power), and the direction of effect is the same in the two studies. We assessed the certainty of evidence as low for this outcome, downgrading for risk of bias (−1) and imprecision (−1) due to wide confidence intervals.
Forest plot of comparison: 1 Adjunctive intravitreal dexamethasone versus antibiotics alone, outcome: 1.2 Snellen visual acuity 6/6 to 6/18.
Albrecht 2011 was the only study to report an outcome related to improvement in visual acuity. For participants in the postcataract group, there was no statistically significant difference in the mean number of Snellen lines of improvement at three months between those who received intravitreous dexamethasone and those who received placebo (4.1 versus 2.7, P = 0.33). Albrecht 2011 did not provide standard deviations (SDs) or standard errors, therefore we could not calculate the estimated mean difference and 95% CI.
Das 1999 reported no visual acuity outcomes except for what was included in the combined anatomical and functional success outcome.
Intraocular pressure
No study reported IOP outcome data at our prespecified time point of three months. One study showed that after 12 months of therapy, IOP changed to 13.9 mmHg (SD 4.5) from 16.3 mmHg (SD 8.7) at baseline in the dexamethasone group, and to 15.8 mmHg (SD 8.1) from 16.3 mmHg (SD 8.0) at baseline in the antibiotics‐alone group (mean difference −1.90, 95% CI −3.78 to 0.07; N = 167; Analysis 1.3) (Manning 2018). Except for what was included in the combined anatomical and functional success outcome in Das 1999, no other studies reported outcomes related to IOP.
We graded the certainty of the evidence for this outcome as low (−2 for imprecision).
Adverse events
Three studies reported the occurrence of adverse events, as described in Table 1 (Albrecht 2011; Gan 2005; Manning 2018). The total numbers of adverse events were 14 out of 111 (12.6%) for those who received dexamethasone versus 12 out of 116 (10.3%) for those who received antibiotics alone. All three retinal detachments (RDs) reported by Albrecht 2011 followed complicated cataract surgery and the use of intravitreous steroids. Since RDs were the only adverse events shared by the three studies, we performed a pooled analysis for this outcome with the postcataract group from Albrecht 2011 and all participants in Gan 2005 and Manning 2018 (Figure 4). The difference in the occurrence of retinal detachment between those who received dexamethasone and those who did not was uncertain (RR 1.41, 95% CI 0.53 to 3.74; Analysis 1.4); we judged the certainty of the evidence for this outcome to be low (−1 for risk of bias, −1 for imprecision).
| Adverse event | Study ID | With dexamethasone | Antibiotics alone |
|---|---|---|---|
| Retinal detachment | 3/17 (17.6%) | 0/14 (0%) | |
| 3/13 (23.1%) | 4/16 (25.0%) | ||
| 2/81 (2.5%) | 2/86 (2.3%) | ||
| Hypotony | 1/13 (7.7%) | 1/16 (6.3%) | |
| Proliferative vitreoretinopathy | 1/13 (7.7%) | 0/16 (0%) | |
| Seclusion of pupil | 0/13 (0%) | 1/16 (6.3%) | |
| Floaters | 2/81 (2.5%) | 1/86 (1.2%) | |
| Pucker | 2/81 (2.5%) | 3/86 (3.5%) |
aIncludes participants from the "post cataract" endophthalmitis group only.
Forest plot of comparison: 1 Adjunctive intravitreal dexamethasone versus antibiotics alone, outcome: 1.3 Retinal detachment.
Gan 2005 also reported the number of participants who underwent a secondary procedure in each intervention group. Three participants in the dexamethasone group underwent a secondary procedure (one vitrectomy and gas for RD, one vitrectomy and silicone oil for persistent inflammation and proliferative vitreoretinopathy, one vitrectomy and silicone oil for RD) compared to four participants in the placebo group (three vitrectomy and silicone oil for RD, one vitrectomy for hypotony).
Similarly, Manning 2018 reported the number of participants who underwent reoperations in each intervention group. Each group had six participants who underwent a vitrectomy; however, each participant had varying indications. Two participants underwent vitrectomies for floaters in the dexamethasone group compared with one participant in the placebo group. Two participants underwent vitrectomies for pucker in the dexamethasone group compared with three participants in the placebo group. Lastly, each group had two participants who underwent vitrectomies for RD.
Das 1999 did not report any adverse events.
Economic data
No trial reported costs associated with the interventions.
Discussion
Summary of main results
In this review, we have presented the results of four RCTs that compared the effects of adjunctive steroid therapy versus antibiotics alone in people with suspected bacterial endophthalmitis after an intraocular procedure. All studies used intravitreous dexamethasone for adjunctive steroid therapy and a combination of intravitreous antibiotics with gram‐positive and gram‐negative bacterial coverage for the antibiotic therapy. Overall, the included trials provided insufficient evidence to either support or refute the use of adjunctive steroids for the treatment of postoperative endophthalmitis (summary of findings Table 1). None of the included studies reported the primary outcome of complete resolution of endophthalmitis as defined in our protocol. One study investigated the effect of adjunctive steroid therapy on the rate of combined functional and anatomical success (as defined by visual acuity and IOP parameters) compared with antibiotics alone, and found no evidence of a difference between groups (Das 1999). A pooled analysis of two studies revealed that adjunctive dexamethasone resulted in a good visual outcome (i.e. Snellen visual acuity of 6/6 to 6/18) at three months compared with antibiotics alone (Albrecht 2011; Gan 2005). Conversely, there was little to no difference between participants who received adjunctive dexamethasone and those who received antibiotics alone in achieving a good visual outcome (visual acuity of 6/6 to 6/18, or LogMAR 0.3 or better) at 12 months (Gan 2005; Manning 2018). One study reported no difference in visual acuity improvement from baseline between the participants treated with versus those treated without steroids (Albrecht 2011). Although one study stratified causative organisms for endophthalmitis between the two intervention groups at one year, the effect of the interventions could not be analyzed because their baseline biopsy results were not provided. Only one study examined IOP, with results suggesting a slight reduction in IOP after 12 months with the use of adjunctive dexamethasone compared with antibiotics alone (Manning 2018). Three studies reported adverse events; the only adverse event shared between the studies was retinal detachment (Albrecht 2011; Gan 2005; Manning 2018). The effect of adjunctive steroid therapy on the occurrence of retinal detachment was uncertain. No study investigated costs associated with the interventions, therefore this outcome remains unknown.
Overall completeness and applicability of evidence
By expanding the inclusion criteria of this review to include participants with acute endophthalmitis after any type of intraocular procedure, we hoped that we would find trials that examined the treatment of endophthalmitis following a variety of intraocular procedures. However, almost all of the included trials reported outcomes for participants who were diagnosed with endophthalmitis after cataract surgery. Also, none of the included studies examined the effect of adjunctive steroid therapy by causative organism. We were therefore unable to address whether adjunctive steroids are useful in certain clinical settings (e.g. specific procedures or causative organisms).
It should be noted that there were some differences in treatment regimens between the different studies, as well as what is considered current practice, which may limit the applicability of the evidence. Currently, a vitrectomy is recommended as soon as endophthalmitis is suspected and prior to intravitreous antibiotics for patients with a presenting visual acuity of light perception only (Barry 2013). Barry and colleagues also favor a vitrectomy for certain cases of acute endophthalmitis even if the presenting visual acuity is better than light perception (Barry 2013). If the patient does not improve within the first 24 to 48 hours, a vitrectomy would usually be considered (if not performed already), or a partial vitrectomy would be expanded to a full vitrectomy (Barry 2013). However, a vitrectomy was performed in the appropriate set of participants in Gan 2005 and Manning 2018. All participants had a vitrectomy prior to intravitreous injection in Das 1999, and no participants had a vitrectomy in Albrecht 2011. There were also differences in the choice of intravitreous antibiotics. All studies used vancomycin, but the second antibiotic used was ceftazidime in Albrecht 2011, amikacin in Das 1999, and gentamicin in Gan 2005 and Manning 2018. Current guidelines recommend using vancomycin and ceftazidime or, rarely, amikacin. Despite their synergistic effects against gram‐positive bacteria when used with vancomycin, aminoglycosides, including amikacin and gentamicin, are less frequently used because of their risk for retinal toxicity. Although gentamicin also provides gram‐negative (including Pseudomonas) coverage, the use of gentamicin could make these two studies less applicable to current practice than the other two studies. Also, the variability in treatment regimen following the additional injection is less than ideal. There are no guidelines on whether to give a second steroid injection, but it is recommended that a second injection of intravitreous antibiotics (antibiotic choice dependent on culture results) be considered in 24 to 48 hours if there is no improvement (Barry 2013). A repeat intravitreous antibiotic injection was only given when necessary in Albrecht 2011 and Das 1999, while all participants had a repeat injection three to four days later in Gan 2005 and Manning 2018.
Inconsistency in the types of outcomes reported and follow‐up intervals made it difficult to combine the studies. Unfortunately, there is no standard way of quantifying resolution or successful management of endophthalmitis. Das 1999's measure of combined anatomical and functional success may be appropriate in a research setting, but may not be useful for determining whether treatment is successful in a clinical setting. Other potential ways of quantifying success are by clinical examination and patient‐reported eye pain (or other quality of life measures). With regard to visual acuity outcomes, we performed pooled analysis on the proportion of participants in each of the Snellen visual acuity groups (as defined by Albrecht 2011 or Manning 2018) at three and 12 months. The evidence regarding visual acuity would have been more complete if visual acuity outcomes at additional time intervals had been reported and shared among studies. Had we been able to examine how visual acuity changed over time between the two intervention groups, we would have a better understanding of whether adjunctive steroid therapy is harmful or beneficial at certain points in the recovery process.
Quality of the evidence
We found two studies at an overall low risk of bias, Albrecht 2011 and Manning 2018, while the other two studies had some methodological limitations (Das 1999; Gan 2005). We considered the evidence for the effect of adjunctive steroid therapy on combined anatomical and functional success to be of very low certainty, downgrading for unclear risk of bias for most outcomes, indirectness of outcome, and imprecision of results with uncertainty in the direction of the true effect. We graded the certainty of the evidence as low for the proportion of participants with visual acuity of 6/6 to 6/18, or LogMAR 0.3 or better, at three and 12 months due to unclear risk of bias and imprecision. We judged the certainty of the evidence for intraocular pressure as low due to imprecision of results. Lastly, we graded the certainty of the evidence for the occurrence of retinal detachment as low due to unclear risk of bias and imprecision of results.
Potential biases in the review process
We did not identify any specific biases. It is likely that all relevant studies have been included in this review, as we used a highly sensitive strategy to search bibliographic databases, clinical trial databases, and reference lists of included studies. Also, two review authors performed major steps of the review process independently in order to minimize bias and errors.
Agreements and disagreements with other studies or reviews
While only four RCTs have compared adjunctive steroid therapy with antibiotics alone for the treatment of acute postoperative endophthalmitis, several non‐randomized studies have studied this comparison. Most studies found that the use of intravitreous steroids had no significant effect on final visual outcome (Dev 2005; Eifrig 2003; Hall 2008; Miller 2004; Pijl 2010). Due to the retrospective nature of these studies, there was a wide range in the follow‐up periods within and among studies, ranging from months to years. Three studies included only patients with postcataract endophthalmitis (Dev 2005; Hall 2008; Pijl 2010), while the other two studies examined those with endophthalmitis caused by a specific organism regardless of etiology: Streptococcus pneumoniae in Miller 2004 and Pseudomonas aeruginosa in Eifrig 2003. The one study that showed a harmful effect of adjunctive steroid therapy was Shah 2000, which found that administering adjunctive steroids in participants with postcataract endophthalmitis resulted in a significant worsening of visual acuity. This negative effect was seen when comparing mean visual acuities at one, three, and six months, as well as comparing the percentage of participants with a 3‐line improvement by one and three months. The Shah 2000 study investigators proposed steroid‐induced toxicity or blunting of the immune response, or both, as possible reasons for their findings. In contrast, one small retrospective case series on culture‐positive Staphylococcus aureus endophthalmitis (note: 26% of participants had non‐acute postoperative endophthalmitis) showed that the addition of intravitreous dexamethasone to intravitreous antibiotics had a significantly beneficial effect on final visual outcome (Mao 1993). Similar to our study, a significant effect was found when examining the proportion with good visual outcome (i.e. visual acuity of 20/50 or better) at last follow‐up time point (mean: 13 months, range: one month to 4.5 years). Another study that observed a beneficial effect of adjunctive steroids examined the use of systemic and topical steroids (Koul 1989), unlike our review. This retrospective, multicenter study in Sweden reported that participants treated with a combination of topical and systemic steroids in conjunction with intravitreous antibiotics had better final visual acuities than those treated with no steroids or only topical steroids. Only a few studies compared the occurrence of adverse events. Dev 2005 reported no difference in the need for a second procedure to manage endophthalmitis and the occurrence of late postoperative complications, while Eifrig 2003 reported no difference in the need for enucleation or evisceration.
More recently, Robbins 2020 performed a retrospective, non‐randomized comparative study in which they evaluated visual outcomes in patients with endophthalmitis who were treated with or without systemic corticosteroid therapy. Investigators found that in 133 eyes with endophthalmitis, 33 (25%) received oral steroids (and 32 of these eyes also received topical steroids). Oral steroid use was associated with an improvement in visual acuity of 3 lines or more after endophthalmitis and a greater improvement comparing visual acuity at presentation to six‐month follow‐up. However, in a retrospective chart review of 63 eyes with endophthalmitis, Moisseiev 2017 found similar improvements in mean visual acuity in the 19 eyes (30%) that received intravitreal antibiotics and dexamethasone versus the eyes that received intravitreal antibiotics alone. Given the heterogeneity of even more recent results and innovations in intraocular surgery techniques and new antibiotics, Soliman 2019 was interested in evaluating current treatment patterns for endophthalmitis. In their multicenter study describing international practice patterns, Soliman 2019 found that in 237 eyes diagnosed with acute endophthalmitis after intraocular surgery or intravitreal injections, all received intravitreal antibiotics on the day of presentation, but only a minority received adjunctive steroid therapies, with 25.3% receiving intravitreal steroids and 21.9% receiving systemic steroids.
In a narrative review of the literature, Rahmani 2018 came to similar conclusions as those of this review, noting that limited small studies have not shown improvement in long‐term visual outcomes with the use of intravitreal steroids. Furthermore, Rahmani 2018 pointed out that although adjunctive steroids are commonly used at the time of diagnosis for more severe cases of endophthalmitis, surgeons should exercise caution and consider the potential for inadequate first‐line antibiotic coverage, and think about waiting until the pathogen and drug sensitivities are identified before using intravitreal steroids.
Considering the paucity of data and heterogeneity of the results, it is not possible to conclude whether intravitreous dexamethasone is beneficial or harmful in the treatment of acute endophthalmitis after intraocular procedure from these studies. A recent review concluded that since most of the current literature does not show an effect of adjunctive steroid therapy, and Shah 2000 showed a detrimental effect, the routine use of adjunctive intravitreous steroids for acute endophthalmitis is not supported at this time (Bui 2014). We agree with Bui 2014 that RCTs at low risk of bias and with adequate power should be completed to clarify whether adjunctive steroid therapy may be helpful in certain clinical settings and should be avoided in others.
Study flow diagram.
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Forest plot of comparison: 1 Adjunctive intravitreal dexamethasone versus antibiotics alone, outcome: 1.2 Snellen visual acuity 6/6 to 6/18.
Forest plot of comparison: 1 Adjunctive intravitreal dexamethasone versus antibiotics alone, outcome: 1.3 Retinal detachment.
Comparison 1: Adjunctive intravitreal dexamethasone versus antibiotics alone, Outcome 1: Resolution of endophthalmitis
Comparison 1: Adjunctive intravitreal dexamethasone versus antibiotics alone, Outcome 2: Visual acuity
Comparison 1: Adjunctive intravitreal dexamethasone versus antibiotics alone, Outcome 3: Intraocular pressure (IOP)
Comparison 1: Adjunctive intravitreal dexamethasone versus antibiotics alone, Outcome 4: Retinal detachment
| Combined steroid and antibiotic therapy compared with antibiotics alone for acute endophthalmitis after intraocular procedure | ||||||
| Population: eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection) Settings: ophthalmology clinic or hospital Intervention: steroids plus antibiotics Comparison: antibiotics alone | ||||||
| Outcomes* | Illustrative comparative risks** (95% CI) | Relative effect | No. of participants | Certainty of the evidence | Comments | |
|---|---|---|---|---|---|---|
| Assumed risk | Corresponding risk | |||||
| Antibiotics alone | Combined steroid and antibiotic therapy | |||||
| Complete resolution of endophthalmitis at 3 months' follow‐up | 813 per 1000 | 878 per 1000 | RR 1.08 | 32 | ⊕⊝⊝⊝ | Assessed as combined anatomical and functional success, where anatomical success was defined as IOP of at least 5 mmHg, and functional success was defined as visual acuity of at least 6/120 |
| Visual acuity 6/6 to 6/18 at 3 months' follow‐up | 300 per 1000 | 585 per 1000 | RR 1.95 | 60 | ⊕⊕⊝⊝ |
|
| Visual acuity 6/6 to 6/18, or LogMAR 0.3 or better at 12 months' follow‐up | 627 per 1000 | 710 per 1000 (704 to 750) | RR 1.12 | 195 | ⊕⊕⊝⊝ |
|
| Improvement in visual acuity at 3 months' follow‐up | See comment | Investigators of 1 study reported improvement in visual acuity, but the effect of adjunctive steroid therapy could not be estimated because the study investigators did not provide standard deviations or standard errors. | ||||
| Intraocular pressure at 12 months' follow‐up | The mean IOP was 15.8 mmHg. | The mean IOP was on average 1.90 lower (95% CI −3.78 to 0.07). | － | 167 | ⊕⊝⊝⊝ |
|
| Adverse events at 3 to 12 months' follow‐up | 52 per 1000 | 72 per 1000 | RR 1.41 | 227 | ⊕⊕⊝⊝ | Data are for retinal detachment. Other reported adverse events included hypotony (2/29 participants), proliferative vitreoretinopathy (1/29 participants), seclusion of pupil (1/29 participants), floaters (3/167 participants), and pucker (5/167 participants). |
| Costs associated with the interventions at 3 months' follow‐up | No data were available for this outcome. |
| ||||
| *The primary follow‐up time point for the review was 1 month; however, none of the included trials reported outcomes at this time point. Data are presented for the follow‐up time point for which data were available. CI: confidence interval; IOP: intraocular pressure; RR: risk ratio | ||||||
| GRADE Working Group grades of evidence | ||||||
| 1Downgraded (−1) for unclear risk of bias in the trials. | ||||||
| Adverse event | Study ID | With dexamethasone | Antibiotics alone |
|---|---|---|---|
| Retinal detachment | 3/17 (17.6%) | 0/14 (0%) | |
| 3/13 (23.1%) | 4/16 (25.0%) | ||
| 2/81 (2.5%) | 2/86 (2.3%) | ||
| Hypotony | 1/13 (7.7%) | 1/16 (6.3%) | |
| Proliferative vitreoretinopathy | 1/13 (7.7%) | 0/16 (0%) | |
| Seclusion of pupil | 0/13 (0%) | 1/16 (6.3%) | |
| Floaters | 2/81 (2.5%) | 1/86 (1.2%) | |
| Pucker | 2/81 (2.5%) | 3/86 (3.5%) | |
| aIncludes participants from the "post cataract" endophthalmitis group only. | |||
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
| 1.1 Resolution of endophthalmitis Show forest plot | 2 | Risk Ratio (M‐H, Fixed, 95% CI) | Totals not selected | |
| 1.2 Visual acuity Show forest plot | 3 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 1.2.1 at 3 months | 2 | 60 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.95 [1.05, 3.60] |
| 1.2.2 at 12 months | 2 | 195 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.12 [0.92, 1.37] |
| 1.3 Intraocular pressure (IOP) Show forest plot | 1 | Mean Difference (IV, Fixed, 95% CI) | Totals not selected | |
| 1.4 Retinal detachment Show forest plot | 3 | 227 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.41 [0.53, 3.74] |
